Logo for LaunchBio Program: Larger than Life ScienceLogo for LaunchBio Program: Larger than Life Science

Building a Strong Network for Life Science Innovators


Funding Now Dallas

Market Trends in 2022

Panel 1

Market Intelligence with Patrick Huddie and David Cary

Today’s life science companies face tougher market conditions than we’ve seen in recent years. In Q1, VC investment was down, IPO activity was down and due diligence is taking longer. Many offerings have been put on hold as startups, investors and banks navigate this dramatic market shift. Join us for the latest market intelligence for startups from Dr. Patrick Huddie, Partner at the Westbury Group with David Cary, First Vice President, Financial Advisor – Wealth Management at Morgan Stanley. This expert analysis will address the current market environment for public and private life science companies, the outlook for the next 12 months, and financing options for IPO-ready startups.


  • Patrick Huddie

    Patrick Huddie, PhD, Partner, Westbury Group

    Dr. Patrick Huddie is an experienced investment banker with entrepreneurial and operations experience. He has advised many companies about mergers and acquisitions, including management buyouts and blank check acquisitions, as well as all types of debt and equity finance. His client companies have been in industries as diverse as biotechnology, consumer goods, construction, defense contracting, diagnostics, financial services, information technology and medical devices. He is also a managing member of the Chesapeake Emerging Opportunities Club, an early-stage fund based in Columbia, Maryland with investments in biotechnology, alt. energy, medical devices and wireless tech.

  • David Cary

    David Cary, First Vice President, Financial Advisor Wealth Management, Morgan Stanley

    David Cary, First Vice President, Financial Advisor Wealth Management, Morgan Stanley, manages personal and corporate assets for C-level executives at public corporations and individuals who own private, middle-market businesses. He also provides investment services to foundations, nonprofits and endowments in which clients are involved. He has an undergrad in accounting and an MBA in finance. David began his career as the first full-time accounting employee of a startup computer retailer which pioneered the computer superstore concept and eventually went public.

Panel 2

Funding Fundamentals
Startups have options when it comes to funding sources—and timing is key. Non-dilutive funding sources can supplement financing as a company progresses through stages of growth and can help lengthen the runway between venture rounds in today’s challenging market climate. Develop your funding strategy early and it will pay off in future rounds. Learn from a team of funding professionals on the right time to engage and key elements to develop a cohesive early-stage funding strategy to leverage both non-dilutive and venture financing sources together to conserve capital and make it to your next milestone!


  • Brent Bernell, Partner, DLA Piper

    Brent Bernell, Partner, DLA Piper

    Brent Bernell provides counsel to public and private companies, as well as the institutional investors that help them grow, on the full spectrum of corporate and securities matters, including capital markets, M&A, venture capital financing and public company reporting and corporate governance. Brent’s transactional practice includes representing issuers and underwriters in registered and unregistered public equity and debt offerings, strategic and financial buyers and sellers in mergers and acquisitions and private companies and institutional investors in venture capital and private equity investments.

  • Tai-Li Chang, MD, MBA, Partner, Highside Capital Management

    Tai-Li Chang, MD, MBA, Partner, Highside Capital Management

    Tai-Li is a Partner at Highside Capital Management, a former institutional hedge fund that managed $5B assets under management (at peak) that spun out of Maverick Capital and is currently a family office, since 2016, where he leads its direct investment efforts. From 2015-2016, Tai-Li was a Managing Director at Hayman Capital Management LP, an institutional multi-strategy hedge fund, where he led the firm’s biotech investments. From 2012-2015, he invested in private and illiquid public biotech companies at Venrock, starting out as a Senior Associate after Harvard Business School and was promoted to VP. Prior to medical school and after college, he worked in investment banking at Morgan Stanley.

  • Kelsey Haley, MA, Regional Director, CSC Leasing

    Kelsey Haley, MA, Regional Director, CSC Leasing

    Kelsey Haley is the Regional Director for CSC Leasing for the Southwest and supports early-stage companies and beyond with financing solutions. Kelsey serves as an Advisory Council Member for Beam Founders Angel Network, an investment organization focused on women-founded companies. Additionally, Kelsey is a Limited Partner in The Fund, a first of its kind venture fund created and fueled by its members that invests in early stage technology companies. Kelsey has an extensive background in sales as well as non-profit organizations.

  • Annie Kadota, Sr. Vice President, Silicon Valley Bank

    Annie Kadota, Sr. Vice President, Silicon Valley Bank

    Annie Kadota is a Senior Vice President in Silicon Valley Bank’s Life Science and Healthcare Banking Solutions group, where her specialty in venture debt supports the team’s deep expertise in providing financial solutions to high-growth public and private life science companies. Annie joined Silicon Valley Bank in 2014 based in the Bay Area and returned to her hometown of San Diego in 2015 to join the Life Science Practice. While in San Diego, she served as committee chair for the Southern California chapter of Women in Bio, which promotes careers, leadership and entrepreneurship in the second-largest biotech hub in the United States.


no tags added to this event